Recent Finacing
Recent Raise
Immvira develops next‑generation oncolytic herpesvirus therapies and OvPENS-derived drug carriers, advancing intratumoral and systemic oHSV candidates for solid tumors, brain tumors, and hematologic malignancies in clinical trials.
